
BSX
Boston Scientific Corporation
$105.50
-$0.25(-0.24%)
51
Overall
40
Value
63
Tech
--
Quality
Market Cap
$157.64B
Volume
4.07M
52W Range
$80.50 - $108.94
Target Price
$125.13
Order:
Income Statement
Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
Total Revenue | $7.5B | $8.4B | $9.0B | $9.8B | $10.7B | $9.9B | $11.9B | $12.7B | $14.2B | $16.7B | ||
Total Revenue | $7.5B | $8.4B | $9.0B | $9.8B | $10.7B | $9.9B | $11.9B | $12.7B | $14.2B | $16.7B | ||
COST OF GOODS SOLD | ||||||||||||
Cost of Revenue | $2.2B | $2.4B | $2.6B | $2.8B | $3.1B | $3.5B | $3.7B | $4.0B | $4.3B | $5.3B | ||
GROSS PROFIT | ||||||||||||
Gross Profit | $5.3B | $6.0B | $6.5B | $7.0B | $7.6B | $6.4B | $8.2B | $8.7B | $9.9B | $11.5B | ||
OPERATING EXPENSES | ||||||||||||
Operating Expenses | $5.6B | $5.5B | $5.2B | $5.5B | $6.1B | $6.5B | $7.0B | $6.7B | $7.6B | $8.9B | ||
Research & Development | $876.0M | $920.0M | $997.0M | $1.1B | $1.2B | $1.1B | $1.2B | $1.3B | $1.4B | $1.6B | ||
Research Expense | $876.0M | $920.0M | $997.0M | $1.1B | $1.2B | $1.1B | $1.2B | $1.3B | $1.4B | $1.6B | ||
Selling, General & Administrative | $2.9B | $3.1B | $3.3B | $3.6B | $3.9B | $3.8B | $4.4B | $4.5B | $5.2B | $6.0B | ||
General & Administrative Expenses | $2.9B | $3.1B | $3.3B | $3.6B | $3.9B | $3.8B | $4.4B | $4.5B | $5.2B | $6.0B | ||
Salaries & Wages | $-28.0M | $-29.0M | $-32.0M | $-21.0M | $-24.0M | $-28.0M | $-29.0M | -- | -- | -- | ||
Depreciation & Amortization | $495.0M | $545.0M | $565.0M | $599.0M | $699.0M | $789.0M | $741.0M | $803.0M | $828.0M | $856.0M | ||
Depreciation & Amortization | $495.0M | $545.0M | $565.0M | $599.0M | $699.0M | $789.0M | $741.0M | $803.0M | $828.0M | $856.0M | ||
Amortization | $495.0M | $545.0M | $565.0M | $599.0M | $699.0M | $789.0M | $741.0M | $803.0M | $828.0M | $856.0M | ||
Other Operating Expenses | $26.0M | $79.0M | $68.0M | $70.0M | $65.0M | $45.0M | $49.0M | $47.0M | $46.0M | $33.0M | ||
OPERATING INCOME | ||||||||||||
Operating income | $-327.0M | $447.0M | $1.3B | $1.5B | $1.5B | $-80.0M | $1.2B | $1.6B | $2.3B | $2.6B | ||
EBITDA | $439.0M | $1.2B | $2.0B | $2.6B | $2.2B | $1.4B | $2.5B | $2.8B | $3.4B | $3.9B | ||
NON-OPERATING ITEMS | ||||||||||||
Interest Expense (Non-Operating) | $284.0M | $233.0M | $229.0M | $241.0M | $473.0M | $361.0M | $341.0M | $470.0M | $265.0M | $305.0M | ||
Net Non-Operating Interest Income/Expense | $-284.0M | $-233.0M | $-229.0M | $-241.0M | $-473.0M | $-361.0M | $-341.0M | $460.0M | $-265.0M | $-305.0M | ||
Gain on Sale of Securities | $2.0M | $12.0M | -- | -- | -- | $363.0M | $-178.0M | -- | -- | -- | ||
Other Income/Expense | $181.0M | $77.0M | $48.0M | $-142.0M | $428.0M | $-2.0M | $-62.0M | $-434.0M | $116.0M | $381.0M | ||
Other Special Charges | $-39.0M | $-37.0M | $-124.0M | $156.0M | $-358.0M | $362.0M | $218.0M | $-38.0M | $-358.0M | $-321.0M | ||
SPECIAL ITEMS | ||||||||||||
Restructring And Mn A Income | $26.0M | $28.0M | $37.0M | $36.0M | $38.0M | $52.0M | $40.0M | $24.0M | $69.0M | $16.0M | ||
Special Income Charges | $-1.1B | $-832.0M | $-322.0M | $-139.0M | $-153.0M | $-403.0M | $-470.0M | $-197.0M | $42.0M | $-16.0M | ||
Impairment of Capital Assets | -- | -- | -- | -- | -- | $73.0M | -- | -- | -- | -- | ||
PRE-TAX INCOME | ||||||||||||
EBIT | $-366.0M | $410.0M | $1.2B | $1.7B | $1.2B | $282.0M | $1.4B | $1.6B | $2.2B | $2.6B | ||
Pre-Tax Income | $-650.0M | $177.0M | $933.0M | $1.4B | $687.0M | $-79.0M | $1.1B | $1.1B | $2.0B | $2.3B | ||
INCOME TAX | ||||||||||||
Tax Provision | $-411.0M | $-170.0M | $828.0M | $-249.0M | $-4.0B | $2.0M | $36.0M | $443.0M | $393.0M | $436.0M | ||
NET INCOME | ||||||||||||
Net Income | $-239.0M | $347.0M | $104.0M | $1.7B | $4.7B | $-82.0M | $1.0B | $698.0M | $1.6B | $1.9B | ||
Net Income (Continuing Operations) | $-239.0M | $347.0M | $104.0M | $1.7B | $4.7B | $-115.0M | $985.0M | $698.0M | $1.6B | $1.8B | ||
Net Income (Discontinued Operations) | $-239.0M | $347.0M | $104.0M | $1.7B | $4.7B | $-82.0M | $1.0B | $698.0M | $1.6B | $1.9B | ||
Net Income (Common Stockholders) | $-151.0M | $347.0M | $104.0M | $1.7B | $4.7B | $-115.0M | $985.0M | $642.0M | $1.6B | $1.9B | ||
Normalized Income | $212.0M | $879.0M | $852.5M | $1.3B | $-3.1B | $727.6M | -- | -- | -- | -- | ||
TOTALS | ||||||||||||
Total Expenses | $7.8B | $7.9B | $7.8B | $8.3B | $9.2B | $10.0B | $10.7B | $10.6B | $11.9B | $14.1B | ||
SHARE & EPS DATA | ||||||||||||
Average Shares Outstanding | $1.3B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.5B | ||
Average Shares Outstanding (Diluted) | $1.3B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.5B | ||
Shares Outstanding | $1.3B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.5B | ||
Basic EPS | $-0.18 | $0.26 | $0.08 | $1.21 | $3.38 | $-0.08 | $0.69 | $0.45 | $1.08 | $1.26 | ||
Basic EPS (Continuing Operations) | $-0.18 | $0.26 | $0.08 | $1.21 | $3.38 | $-0.08 | $0.69 | $0.45 | $1.08 | $1.26 | ||
Diluted EPS | $-0.18 | $0.25 | $0.08 | $1.19 | $3.33 | $-0.08 | $0.69 | $0.45 | $1.07 | $1.25 | ||
Diluted EPS (Continuing Operations) | $-0.18 | $0.25 | $0.08 | $1.19 | $3.33 | $-0.08 | $0.69 | $0.45 | $1.07 | $1.25 | ||
OTHER METRICS | ||||||||||||
Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | $33.0M | $55.0M | $55.0M | $23.0M | -- | ||
Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | $78.0M | $-22.0M | -- | -- | ||
Minority Interests | $6.3B | $6.7B | $7.0B | $8.7B | $13.9B | $15.3B | -- | -- | $1.0M | $8.0M | ||
Non Recurring Operation Expense | $1.1B | $804.0M | $285.0M | $103.0M | $115.0M | $278.0M | $430.0M | $173.0M | $-111.0M | -- | ||
Other Gand A | $2.9B | $3.1B | $3.3B | $3.6B | $3.9B | $3.8B | $4.4B | $4.5B | $5.2B | $6.0B | ||
Other Impairment Of Capital Assets | $19.0M | $11.0M | $4.0M | $35.0M | $105.0M | $460.0M | $370.0M | $132.0M | $58.0M | $386.0M | ||
Other Write Off | -- | -- | -- | -- | $17.0M | $27.0M | $25.0M | -- | -- | -- | ||
Otherunder Preferred Stock Dividend | -- | -- | -- | -- | -- | $33.0M | $55.0M | $55.0M | $23.0M | -- | ||
Preferred Stock Dividends | -- | -- | -- | -- | -- | $33.0M | $55.0M | $55.0M | $23.0M | -- | ||
Rent And Landing Fees | $76.0M | $80.0M | $88.0M | $92.0M | $80.0M | -- | -- | -- | -- | -- | ||
Write Down | -- | -- | -- | -- | $-19.0M | -- | -- | -- | -- | -- | ||
Restruct | $26.0M | $28.0M | $37.0M | $36.0M | $38.0M | $52.0M | $40.0M | $24.0M | $69.0M | $16.0M |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | BSX | $105.50 | -0.2% | 4.07M |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Boston Scientific Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW